Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00065442
Status:
COMPLETED
Last Update Posted:
2010-09-06
First Post:
2003-07-23
Brief Title:
Provenge Sipuleucel-T Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Sponsor:
Dendreon
Organization:
Dendreon
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Prostate Cancer |
Keywords:
| Name | View |
|---|---|
| biotech | View |
| prostate cancer | View |
| prostate | View |
| AIPC | View |
| androgen-independent | View |
| androgen independent | View |
| hormone insensitive | View |
| hormone-insensitive | View |
| PSA | View |
| prostatic adenocarcinoma | View |
| hormone-refractory | View |
| hormone refractory | View |
| HRPC | View |
| LHRH | View |
| immune therapy | View |
| immunotherapy | View |
| vaccine | View |
| dendritic cells | View |
| antigen-presenting cells | View |
| antigen presenting cells | View |
| cancer vaccine | View |
| therapeutic vaccine | View |
| therapeutic cancer vaccine | View |
| recombinant | View |
| biological | View |
| biopharmaceutical | View |
| biotechnology | View |